An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO), offers timely clinical direction to ASCO's oncologists following publication or presentation of potentially practicechanging data from major studies. This PCO addresses the utility of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy with cetuximab or panitumumab (see Note).
INTRODUCTION
The American Society of Clinical Oncology (ASCO) has established a rigorous, evidence-based approach-the provisional clinical opinion (PCO)-to offer a rapid response to emerging data in clinical oncology. The PCO is intended to offer timely clinical direction to ASCO's oncologists following publication or presentation of potentially practice-changing data from major studies (Appendix).
This PCO addresses only the utility of testing for mutations in codons 12 or 13 of the KRAS gene in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy, that is, cetuximab or panitumumab.
STATEMENT OF THE CLINICAL ISSUE
Results from phase II and III clinical trials of the anti-EGFR MoAbs cetuximab and panitumumab when used either as monotherapy or in combination with chemotherapy, have shown that patients with metastatic colorectal carcinoma may benefit from these therapies and both agents are approved by the US Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer. Stratified analyses of data from these trials by KRAS mutational status-not detected ("wild type") or abnormal (mutated)-indicated that patients with KRAS mutation in codon 12 or 13 did not derive benefit from treatment with cetuximab or panitumumab.
ASCO'S PROVISIONAL CLINICAL OPINION
Based on a systematic review of the relevant literature, all patients with metastatic colorectal carcinoma who are candidates for anti-EGFR monoclonal antibody therapy should have their tumor tested for KRAS mutations in a CLIA-accredited laboratory. If KRAS mutation in codon 12 or 13 is detected, then patients with metastatic colorectal carcinoma should not receive anti-EGFR monoclonal antibody therapy as part of their treatment.
LITERATURE REVIEW AND ANALYSIS
The review of the evidence on which this PCO is based consists primarily of the rigorous systematic review of the literature conducted by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC).
1-10 Details of the BCBSA TEC assessment can be found in the full TEC report, which is available at www .bcbs.com/blueresources/tec/press/KRAS-mutations-epidermal.html. In summary, the TEC searched MEDLINE through October 2008 to identify all relevant articles on anti-EGFR MoAb therapy and KRAS mutation analysis. The TEC supplemented its review by searching for relevant abstracts from the ASCO 2008 Annual Meeting via the online database (www.asco.org/vm). Studies were included in the TEC assessment if they were peer-reviewed, fulllength, English-language articles and investigated response to anti-EGFR MoAbs among patients with metastatic colorectal cancer with respect to KRAS mutational status. The TEC also included phase II and III randomized clinical trials from the 2008 ASCO Annual Meeting if the full presentation slides were available online.
The TEC review identified post hoc analyses on subsets from five randomized, controlled trials (RCTs) of cetuximab or panitumumab that evaluated outcomes for patients with metastatic colorectal cancer in relation to KRAS mutational status (Table 1) ; and five single-arm studies that retrospectively evaluated treatment response according to KRAS status (Table 2) . Two broad findings emerged from the TEC assessment of these studies: (1) a consistent correlation between presence of a KRAS mutation in codon 12 or 13 and lack of response to anti-EGFR MoAb therapy in patients with metastatic colorectal cancer; and (2) evidence of improved tumor response, progression-free, and/or overall survival in response to anti-EGFR MoAb therapy only in those patients with no mutation in codon 12 or 13 (wild type) versus abnormal (mutated) KRAS tumors in analyses from four of five RCTs.
Oncologists should understand that both the PCO and the TEC review are based on assays that detect mutations in codons 12 and 13 of KRAS only. Mutations also occur, although uncommonly, at codons 61 and 146, and these also activate KRAS. In addition, the PCO and the TEC review do not evaluate the differences in sensitivity and specificity among the various assays that are available for KRAS mutation testing 18 and expression of epiregulin or amphiregulin 7 that may indicate response). These subjects are either the focus of current research, or there are insufficient data to justify an opinion at present.
• Freshly extracted from patient, provided fresh or in RNA preservation solution such as RNAlater • Freshly extracted from patient and rapidly frozen and stored frozen • Neutral buffered formalin fixed and paraffin embedded, area of interest selected specifically by the pathologist Acceptable assay types. In all cases, DNA is first extracted by laboratory specific and standardized protocols that incorporate standards to assure adequate and specific extraction.
• Real-time polymerase chain reaction. In real-time polymerase chain reaction, fluorescent probes specific for the most common mutations in codons 12 and 13 are utilized. When a mutation is present, the probe binds and fluorescence is detected.
• Direct sequencing analysis. KRAS mutations can also be identified using a direct sequencing method of exon 1 in the KRAS gene. This technique identifies all possible mutations in the exon.
• At this time, there are no FDA-approved tests for KRAS testing, but KRAS testing can be performed using laboratorydeveloped tests. Outside the United States, a United Kingdom-based company, DxS, offers a kit (TheraScreen) for its KRAS mutations assay. DxS and other vendors are expected to seek US Food and Drug Administration approval for their assays • Choice of assay defined by which assay the laboratory has validated and routinely uses. Oncologist should consult with laboratory about specific test name to order.
Assay Reporting KRAS normal. No mutation was identified. Report will specify assay type and controls used.
KRAS abnormal. Treatment with anti-EGFR monoclonal antibody therapy is not recommended based on the ASCO PCO. Mutation was found. Report will specify what mutation was found, what assay was done, and what controls were used. 
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